Does Abilify Cause Drooling?
Yes, aripiprazole (Abilify) can cause drooling (hypersalivation/sialorrhea), particularly in pediatric patients, though it is less common in adults.
Incidence and Population Affected
The FDA drug label explicitly lists increased saliva or drooling as a common side effect in children 1. The evidence shows clear age-related differences:
Pediatric Patients
- Drooling occurs in 9% of children (6-17 years) with autistic disorder treated with aripiprazole versus 0% with placebo 1
- Salivary hypersecretion occurs in 6% of children with autistic disorder versus 1% with placebo 1
- In pediatric bipolar mania patients (10-17 years), salivary hypersecretion occurred in 6% on aripiprazole versus 0% on placebo 1
- The effect shows dose-dependency: in bipolar mania, rates increased from 0% (placebo) to 3.1% (10 mg) to 8.1% (30 mg) 1
Adult Patients
Drooling is not listed among common adverse reactions in adults with schizophrenia, bipolar disorder, or major depressive disorder in the FDA label 1. This suggests it is either rare or clinically insignificant in adult populations.
Mechanism and Clinical Context
While aripiprazole itself causes drooling less frequently than other antipsychotics, the mechanism differs from typical antipsychotic-induced sialorrhea:
- Extrapyramidal symptoms (EPS) can cause drooling through impaired swallowing rather than increased saliva production 2, 3
- One case report documented severe parkinsonian symptoms including "drooling of saliva" in a 19-year-old patient on 20 mg aripiprazole daily 2
- When drooling occurs with rigidity, tremor, or masked facies, it represents EPS-related impaired swallowing rather than true hypersalivation 2
Clinical Management Algorithm
When drooling occurs on aripiprazole:
Assess for EPS: Look for rigidity, tremor, bradykinesia, or masked facies suggesting parkinsonian symptoms 2
- If EPS present: Consider dose reduction or anticholinergic medication
- EPS-related drooling typically resolves within one week of stopping aripiprazole 2
Consider patient age: Drooling is significantly more common in children, particularly those with autism spectrum disorder 1, 4
Evaluate dose-response: Higher doses (especially 30 mg) show increased rates of salivary hypersecretion in pediatric patients 1
Weigh against benefits: In autism, aripiprazole reduces irritability, hyperactivity, and stereotypies, but drooling must be balanced against these benefits 4
Important Caveats
- Polypharmacy increases risk: When aripiprazole is combined with other antipsychotics, hypersalivation rates increase 5
- Not the worst offender: Clozapine, olanzapine, and quetiapine cause significantly more drooling than aripiprazole 3
- Distinguish true hypersalivation from dysphagia: True increased saliva production versus inability to swallow normal amounts requires different management 3
The evidence consistently shows that while aripiprazole can cause drooling, it occurs predominantly in pediatric populations and is generally less problematic than with other antipsychotics. When it does occur, assess for underlying EPS and consider dose adjustment before discontinuation.